Home › Dompé Announces The EMA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Retinitis Pigmentosa
 

Keywords :   


Dompé Announces The EMA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Retinitis Pigmentosa

2013-07-01 09:05:00| drugdiscoveryonline News Articles

Dompé, a leading company in research & development of novel treatment solutions for rare diseases, announces its investigational drug based on the recombinant human nerve growth factor (rhNGF) for the treatment of retinitis pigmentosa (RP) has been granted orphan drug designation

Tags: treatment drug granted announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.11Hurricane Rafael Update Statement
06.11Summary for Hurricane Rafael (AT3/AL182024)
06.11Warning millions will struggle to pay water bill rises
06.11Atlantic Tropical Weather Outlook
06.11Tropical Storm Rafael Graphics
06.11Tropical Storm Rafael Public Advisory Number 9A
06.11Summary for Tropical Storm Rafael (AT3/AL182024)
06.11Eastern North Pacific Tropical Weather Outlook
More »